Laxminarayan Rawat

Targeting CD70 in cancer: Mechanisms of immune escape and translational opportunities

Akash Sabarwal, Saba Tabasum, Laxminarayan Rawat, Soumitro Pal

Abstract CD70, a tightly regulated immune co‐stimulatory ligand under physiological conditions, becomes aberrantly and persistently overexpressed in a wide spectrum of malignancies, including renal cell carcinoma (RCC), glioblastoma and acute myeloid leukaemia. This tumour‐restricted expression pattern, coupled with its potent immunomodulatory effects, …

us (code pays fourni par la source)

Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress

Akash Sabarwal, Marc Machaalani, Laxminarayan Rawat, Johannes Wedel et autres

us, de (code pays fourni par la source)

Honokiol in cancer: Roles in enhancing combination therapy efficacy and preventing post-transplant malignancies

Laxminarayan Rawat, Raghu Solanki, Rahul Kumar, Soumitro Pal et autres

Therapeutic resistance remains a significant challenge in cancer treatment, often resulting in relapse and poor outcomes. Conventional chemotherapies, such as cisplatin and paclitaxel, are frequently undermined by the development of chemoresistance and systemic toxicity. Targeted therapies, such as receptor tyrosine kinase (RTKs) …

us, in (code pays fourni par la source)

A comprehensive review of anti-cancer mechanisms of polyphenol honokiol and nano carrier-based approaches to enhance its therapeutic potential

Raghu Solanki, Laxminarayan Rawat, Saba Tabasum, Soumitro Pal et autres

in, us (code pays fourni par la source)

AXL signaling in cancer: from molecular insights to targeted therapies

Monika Yadav, Ketki Patne, Saba Tabasum, Jyoti Suryavanshi et autres

AXL, a member of the TAM receptor family, has emerged as a potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays a significant role in various tumor-promoting pathways, including cancer cell proliferation, invasion, metastasis, epithelial-mesenchymal transition …

in, us (code pays fourni par la source)

49 Inhibition of AXL along with c-Met potentially halts resistance development in renal cell carcinoma

Marc Machaalani, Akash Sabarwal, Laxminarayan Rawat, Murugabaskar Balan et autres

Abstract Background c-Met, a receptor tyrosine kinase (RTK), is overexpressed in renal cell carcinoma (RCC) and correlates with a decreased survival rate. Upon binding to its specific ligand, Hepatocyte Growth Factor (HGF), c-Met activates pro-tumorigenic signaling pathways. Cabozantinib (Cabo) inhibits c-Met and …

us (code pays fourni par la source)

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Rahul Kumar, Harsh Goel, Raghu Solanki, Laxminarayan Rawat et autres

During the past two decades, significant advances have been made in the discovery and development of targeted inhibitors aimed at improving the survival rates of cancer patients. Among the multitude of potential therapeutic targets identified thus far, Receptor Tyrosine Kinases (RTKs) are …

in, us (code pays fourni par la source)

Abstract 4555: c-Met/AXL crosstalk in mediating therapeutic resistance in renal cell carcinoma

Akash Sabarwal, Laxminarayan Rawat, Johannes Wedel, Murugabaskar Balan et autres

Abstract Receptor Tyrosine Kinase (RTK), c-Met, is overexpressed in renal cancer and correlates with a decreased survival rate. Upon binding with its specific ligand, Hepatocyte Growth Factor (HGF), c-Met activates pro-tumorigenic signaling. c-Met/RTK inhibitors are used for the treatment of advanced renal …

us (code pays fourni par la source)

A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress

Laxminarayan Rawat, Murugabaskar Balan, Yuzuru Sasamoto, Akash Sabarwal et autres

Receptor tyrosine kinase (RTK), c-Met, is overexpressed and hyper active in renal cell carcinoma (RCC). Most of the therapeutic agents mediate cancer cell death through increased oxidative stress. Induction of c-Met in renal cancer cells promotes the activation of redox-sensitive transcription factor …

us (code pays fourni par la source)

Abstract 3866: Targeting AXL can effectively inhibit c-Met-induced therapeutic resistance in renal cancer

Akash Sabarwal, Laxminarayan Rawat, Johannes Wedel, Yuzuru Sasamoto et autres

Abstract Advanced stage renal cell carcinoma (RCC) often becomes resistant to the currently available therapeutic options. Receptor Tyrosine Kinase (RTK), c-Met, is overexpressed and hyperactivated in renal cancer; and it promotes tumor-promoting pathways following binding with its ligand, Hepatocyte Growth Factor (HGF). …

us (code pays fourni par la source)

Piperlongumine induces ROS mediated apoptosis by transcriptional regulation of SMAD4/P21/P53 genes and synergizes with doxorubicin in osteosarcoma cells

Laxminarayan Rawat, Vijayashree Nayak

in (code pays fourni par la source)

Ursolic acid disturbs ROS homeostasis and regulates survival-associated gene expression to induce apoptosis in intestinal cancer cells

Laxminarayan Rawat, Vijayashree Nayak

Abstract Ursolic acid is a natural compound possessing several therapeutic properties including anticancer potential. In present study, cytotoxic and antimetastatic properties of ursolic acid were investigated in intestinal cancer cell lines INT-407 and HCT-116. The cells growth and number were decreased in …

in (code pays fourni par la source)